Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (June 2023)
19 slides from Pyc Therapeutics's investor presentation, Jun 16, 2023
Slide 1: Life-changing science: Q2 Investor Update
For personal use only Life-changing science Q2 Investor Update June 2023
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 3: Discussion topics – Q2 investor update
Discussion topics – Q2 investor update • Introduction to PYC Therapeutics For personal use only • Vision • Strategy • Commercial framework • Pipeline review • PYC’s progress YTD 2023 • Forward view for PYC in 2023 • Q&A PYC THERAPEUTICS 3
Slide 4: PYC's vision
For personal use only Life-changing science PYC’s vision
Slide 5: PYC discovers and develops RNA therapies for genetic diseases
For personal use only PYC discovers and develops RNA therapies to change the lives of patients with genetic diseases PYC THERAPEUTICS 5
Slide 6: First-in-class drug candidates progressing into the clinic within 18 months
PYC is progressing 3 first-in-class drug candidates with disease-modifying potential into the clinic within 18 months PYC IS HERE Scale into multiple clinical For personal use only 3 safety and efficacy read-outs Evolution to a clinical- 2 stage multi-asset company 2023/24 Objectives • Establish hum
Slide 7: PYC's strategy
For personal use only Life-changing science PYC’s strategy
Slide 8: PYC's RNA delivery platform overcomes the primary challenge for precision therapies
PYC’s RNA delivery platform overcomes the primary challenge for precision therapies – ensuring enough drug reaches its target For personal use only PYC combines existing RNA drug design PYC’s drug delivery platform is used to assist technology with its proprietary drug delivery the RNA drug reach it
Slide 9: Strategy anchored on four critical features
PYC is creating therapies for patients through a strategy anchored on four critical features For personal use only A HIGHER PROBABILITY A FASTER PATH LIKELY RAPID UPTAKE ORPHAN DRUG OF SUCCESS TO MARKET IN MARKET PRICING PYC focuses on The potential for First-in-class drugs in Median list price of m
Slide 10: Powerful forces converging around PYC's programs
4 powerful forces are converging around PYC’s programs that enhance their prospects of success in clinical development For personal use only 1. Facilitating the delivery of RNA drugs to their target cell 4. Using patient- 2. Applying RNA derived models PYC’s drugs in the to validate these drugs befo
Slide 11: Facilitating delivery of RNA drugs to their target cell
1. Facilitating the delivery of RNA drugs to their target cell substantially enhances the prospect of disease-correction For personal use only “My view of the next 20 years is that we are going to a see a remarkable expansion of gene, cell, gene editing and RNA-based strategies in medicine that emer
Slide 12: RNA drugs to increase gene expression gaining appreciation
2. The specific application of RNA drugs to increase gene expression is gaining increased appreciation For personal use only PYC THERAPEUTICS 12 Khorkova, O., Stahl, J., Joji, A. et al. Amplifying gene expression with RNA-targeted therapeutics. Nat Rev Drug Discov (2023). https://doi.org/10.1038/s41
Slide 13: Genetic validation of the target
3. Genetic validation of the target remains the single most important consideration informing success in the clinic For personal use only Like Alnylam, PYC pursues drug targets with the highest degree of genetic validation 13 Harnessing Human Genetics to Power the Next Wave of RNAi Therapeutics, Aln
Slide 14: Patient-derived models give early insight into efficacy
4. The use of patient-derived models provides an early insight into efficacy of the drug candidate in the clinic For personal use only Program #1 (RP11) patient-organoid Program #2 (ADOA) patient-derived model Nuclear stain PRPF31 Untreated RP11 Untreated Treated VP-001 treated (Low dose) VP-001 tre
Slide 15: Commercial implications
For personal use only Life-changing science Commercial implications
Slide 16: Each program directed towards a $1 billion+ addressable market
Each of the programs in PYC’s pipeline is directed towards a $1 billion+ addressable market¹ Current progress Progress expected in 2023 For personal use only Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 Retinitis Pigmentosa Type 11 PYC-001 OPA1 Aut
Slide 17: Program deep-dives (progress and anticipated milestones)
For personal use only Life-changing science Program deep-dives (progress and anticipated milestones)
Slide 18: Path to progression of first-in-class drugs into the clinic
PYC has mapped out the path to progression of 3 first-in-class drugs with disease-modifying potential into the clinic Human safety data to be generated across 2023 in VP-001 program, with PYC-001 expected to enter For personal use only the clinic in 2024 Program Q1 Q2 Q3 Q4 Q1 Q2 Completion of dosin
Slide 19: Q&A
For personal use only Life-changing science Q&A